AT III in septicemia with DIC.
In the development of sepsis DIC is a common complication. Several studies presented in this paper show a coincidence between the development of DIC and depletion of Antithrombin III, a serine protease inhibitor which inhibits a large scale of activated clotting factors. It seems very probable that substitution therapy should be of benefit in the treatment of sepsis-related DIC and may improve the outcome of septic patients. Physiological and clinical findings are put together to clarify the basic rationale for running clinical trials and future studies.
Schuster
H P
HP
Medizinische Klinik I, Städtisches Krankenhaus Hildesheim, Germany.
D000990:Antithrombin III / Q000276:immunology*; D020152:Antithrombin III Deficiency; D004211:Disseminated Intravascular Coagulation / Q000097:blood / Q000209:etiology / Q000276:immunology* / Q000401:mortality; D006801:Humans; D011379:Prognosis; D018805:Sepsis / Q000150:complications*; D012720:Severity of Illness Index; D015996:Survival Rate
D000990:Antithrombin III